Biomerica reported operating income from continued operations for the quarter ended February 28, 2009 of $214,101 compared to operating income from continued operations of $118,009 in the year-ago
Daiichi Sankyo Company has filed patent infringement litigations against 11 generics companies for the substance patent and usage patent for levofloxacin hydrate. Daiichi Sankyo brought patent infringement actions
The orphan drug designation provides Oasmia with seven year market exclusivity on the indication when the pharmaceutical is approved. The designation is based on the hypothesis that Paclitaxel
Solzira is the subject of a new drug application (NDA) that is under review by the FDA as a potential treatment for moderate-to-severe primary restless legs syndrome (RLS).
As part of the agreement, Syntonix gains access to Zenobia’s technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia has completed three unique protein structures
Simponi is a new, human anti-tumor necrosis factor (TNF) monoclonal antibody that was generated by Medarex’s UltiMAb technology that targets and neutralizes both the soluble and membrane-bound forms
The long-term cardiac monitoring for detection of atrial fibrillation (AF) after cryptogenic stroke is a pilot study involving five centers in Canada and the US. The primary endpoint
Berlin Heart, a developer and distributor of implantable and external ventricular assist devices, has received its first marketing approval in North America. The Excor Pediatric ventricular assist device
David Ramsay, Halozyme’s current CFO, will transition to the new position of vice president of corporate development. Mr Ramsay joined Halozyme as CFO in 2003. Mr Gustafson brings
Mr Beasley has joined Bard in 1989 and advanced through the sales and marketing organizations prior to being promoted to president of Bard Access Systems in 2003 and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.